|
7th Annual Conference Of The British HIV Association [BHIVA]27 – 29 April 2001, The Hove Centre, Brighton |
[AUTHOR(S):] N Larbalestier, J Mullen, S. O'Shea, F Cottam, I Chrystie, A de Ruiter
Guy's and St Thomas' Hospital, London, UK
BHIVA Conf 2001 Apr 27-29;7:O11
OBJECTIVE: To determine the prevalence of ZDV resistance mutations following monotherapy in pregnancy.
METHODS: All pregnant women on ZDV monotherapy at four treatment centres between Nov 1995 and Dec 2000 were identified. Data were abstracted from the medical notes. Stored plasma was genotyped using the Visible Genetics Trugene™ HIV-1 assay and viral subtyping determined by peptide based enzyme immunoassay.
RESULTS: Of 225 pregnancies, 92 received ZDV monotherapy and suitable delivery samples were available on 62 of these. Preliminary data (one centre) on 16/62: mean baseline CD4 390 cells/µl, median viral load (VL) 5510 HIV-2 RNA copies/ml; 12/16 had non-B subtypes. Mean ZDV exposure at delivery was 11 weeks (range 4–21). A single primary mutation was evident in one woman only at codon 215. Full data will be presented (four centres).
CONCLUSIONS: The development of drug resistance in this cohort appears uncommon. The only primary mutation evident occurred in a woman whose baseline VL was high and who, with current guidelines, would now receive highly active antiretroviral therapy. Monotherapy is an attractive intervention to reduce MCT as it limits fetal drug exposure and is well tolerated. In this cohort of asymptomatic women with low VL, future treatment options seem preserved.
PRESENTING AUTHOR: N Larbalestier
010427
O11
Copyright © 2001, 2011 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD